Full Event Guide
Having trouble downloading the brochure? Let us know here and we’ll email it to you instead
New Topics Explored in the 2021 Agenda:
- New treatment paradigms to support schizophrenia patients including the development of SEP-363856, a TAAR1/5-HT1A agonist for the treatment of Schizophrenia
- The intersection of technology and psychedelics: What role will digital technologies play in psychedelic-assisted therapy?
- Repurposing psychoactive natural products as building blocks for next generation therapies to improve mental health
- Investigating sensory ERP biomarkers for disease and target engagement
- Assessing the neuropsychiatric implications of COVID 19
- Exploring additional indications for Substance Use Disorders for drugs already in development for depression, schizophrenia, anxiety, insomnia, and the neuropsychiatric symptoms of Alzheimer’s Disease
- Role of microglia, neuroinflammation and peripheral immune cells in mood disorders
New Speakers? There Are Plenty, Here's a Glimpse:
- Michael De Vivo, Vice President, Neuroscience, BioXcel Therapeutics
- Srinivas Rao, Co-Founder & Chief Scientific Officer, Atai Life Sciences
- Pradeep Nathan, Vice President & Head of Experimental Medicine, Lundbeck, Professor of Neuroscience, Monash University
- Heather Dworak, Senior Director, Clinical Research, Sunovion
- Judith Ford, Co-Director, Brain Imaging & EEG Lab, Professor, Department of Psychiatry, UCSF; Senior Research Career Scientist, San Francisco Veterans Affairs Medical Center